Knee Hurt

Category: Blog

Your blog category

  • Relevance of circulating semaphorin 4A to rheumatoid arthritis response to treatment

    Relevance of circulating semaphorin 4A to rheumatoid arthritis response to treatment

     

    Analysis of cohort 1 from Cochin Hospital, Paris

    Study population

    Between May 2016 and February 2018, a total of 101 patients (85 women, 84%) with established RA were included. These patients had a mean age of 58 ± 13 years, a mean disease duration of 14 ± 11 years, and a mean follow-up age. -from 41 ± 15 months. Positive rheumatoid factors and anti-CCP antibodies were detected in 80 (79%) and 83 (82%) patients, respectively. Erosions were present in 63 (62%) patients; 70 patients (69%) received corticosteroids (including 9 at a dose > 10 mg/day), 78 received conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), including 61 (60%) with MTX, and 59 (58%) received targeted biological DMARDs (bDMARDs). During the inclusion visit, 13 patients initiated a first-line bDMARD or switched to another bDMARD due to inadequate disease control. Detailed characteristics of our study sample are shown in Table 1.

    Table 1 Characteristics of patients from the two cohorts at baseline.

    Results

    The number of annual consecutive visits ranged from 2 to 5 (88 patients with 3 visits, 72 with 4 visits, and 65 with 5 visits). Disease flares occurred in 38 patients during the mean follow-up period of 41 ± 15 months. Of these 38 patients, targeted therapy was added or modified in 26 patients due to inadequate disease control: 10 started on a bDMARD or a targeted synthetic (ts)-DMARD and 16 switched from a bDMARD to a new b- or tsDMARD (Table S1) . The mean time to treatment adaptation was 35 ± 13 months.

    Primary endpoint: evaluation of the predictive value of SEMA4A for the occurrence of treatment failure

    Baseline SEMA4A levels > 94 ng/ml were predictive of treatment failure, defined by the occurrence of flares AND treatment escalation (n = 26 patients), with an HR of 2.73 (95% CI 1.24 –5.96) (Fig. 1A). Results were unchanged after excluding the 13 patients with active disease at baseline who requested addition or change to a bDMARD (HR: 2.83, 95% CI 1.14–7.52).

    Figure 1
    Figure 1

    Predictive value of SEMA4A for the progression of rheumatoid arthritis in Paris cohort 1. (a) Time to treatment failure (defined as flares AND treatment escalation) according to circulating SEMA4A concentrations (≤ or > 94 ng/ml). (b) Survival without disease flare according to circulating SEMA4A concentrations (≤ or > 94 ng/ml).

    Secondary endpoints

    Elevated SEMA4A levels (>94 ng/ml) at baseline were predictive of flare occurrence (n = 34 patients) during the follow-up period (Fig. 1B) with a hazard ratio (HR) of 2.43 (95% confidence interval ). , CI 1.27–4.68). Results were unchanged after excluding the 13 patients with active disease at baseline (HR 2.36, 95% CI 1.15–4.89).

    Baseline SEMA4A concentrations were significantly increased in patients who experienced flares during the follow-up period (78 ± 30 ng/ml vs. 60 ± 24 ng/ml, p < 0.001) (Fig. 2A). SEMA4A levels were also significantly higher in the 13 patients with active disease at baseline who requested the addition or modification of a bDMARD, compared with the 88 patients on stable treatment (84 ± 33 ng/ml vs. 63 ± 26, p = 0.011). Although baseline SEMA4A concentrations were higher in patients experiencing flares AND treatment escalation compared to those on stable treatment (75 ± 31 ng/ml vs. 63 ± 26 ng/ml, p = 0.060), this did not reach significance (Fig. 2B). Patients with elevated SEMA4A levels at baseline maintained higher DAS28 levels throughout the follow-up period, with significant differences at visits 1, 2, and 5 (Fig. 2C).

    Figure 2
    Figure 2

    Baseline circulating SEMA4A levels according to the occurrence of (a) disease flare or (b) treatment failure (defined as flares AND treatment escalation) during the prospective follow-up period in Paris cohort 1. (c) Course of the DAS28 during the follow-up period according to baseline SEMA4A concentrations (≤ or > 94 ng/ml). All data are presented as the mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001, determined by Student’s t-test.

    Integration of SEMA4A with other predictors of treatment failure

    A baseline DAS28 > 3.2 (HR 2.17, 95% CI 1.01–4.72) and the presence of active synovitis, defined by at least grade 2 Doppler activity8, detected at at least one joint on power Doppler ultrasound (PDUS) (HR 3.60, 95% CI 1.07–12.15) were predictive of further treatment failure. These results were not changed after excluding the 13 patients with active disease at baseline.

    Baseline age, disease duration, ACPA or RF positivity, smoking status, presence of erosions, series of targeted DMARDs, corticosteroid treatment, and CRP levels were not predictive of treatment failure (Table 2). Multivariate Cox analyzes adjusted for these covariates confirmed that SEMA4A was the only independent predictor of treatment failure (HR 2.71, 95% CI 1.14–6.43).

    Table 2 Univariate and multivariate Cox analyzes to identify independent predictors of treatment failure (primary endpoint) and RA flares (secondary endpoint) in Paris cohort 1.

    SEM4A was also confirmed as an independent predictor of flares, along with DAS28 and synovial hyperhemia (Table 2).

    We then assessed the possible combination of DAS28, PDUS and SEMA4A concentrations to predict the occurrence of treatment failure and flares (Table 3). The combination that provided the best predictive value was a DAS28 > 3.2 and/or presence of active synovitis on PDUS and/or SEMA4A concentrations > 94 ng/ml (HR 10.42, 95% CI 1.41–76 .94 for treatment failure and 4.88, 95% CI 1.50–15.89 for flares) (Fig. 3A,B). Matrix models also highlighted the ability of the combination of these 3 parameters to predict the occurrence of treatment failure and flares (Fig. S1): Treatment failure and flares of RA occurred in 53% and 73% of patients with DAS28 > 3.2 at baseline and the presence of active synovitis at PDUS and SEMA4A concentrations > 94 ng/ml, respectively. Furthermore, only one patient with a DAS28 ≤ 3.2, no active synovitis and SEMA4A ≤ 94 ng/ml experienced treatment failure and RA attacks.

    Table 3 Predictive value of circulating SEMA4A alone or in combination DAS28-CRP and/or active synovitis on power Doppler ultrasound for the occurrence of treatment failure (primary endpoint) and RA attacks (secondary endpoint) in Paris cohort 1.
    figure 3
    figure 3

    Predictive value of SEMA4A, alone or in combination with a Disease Activity Score (DAS) 28 > 3.2 and/or the presence of active synovitis on power Doppler ultrasound (PDUS) in cohort 1 from Paris. (a) Time to treatment failure (defined as flares AND escalation of treatment) according to circulating SEMA4A concentrations (> 94 ng/ml) and/or a DAS28 > 3.2 and/or the presence of active synovitis on PDUS. (b) Survival without disease flare according to circulating SEMA4A concentrations (> 94 ng/ml) and/or a DAS28 > 3.2 and/or the presence of active synovitis on PDUS.

    Predictive value of SEMA4A in the subgroup of patients with low disease activity or remission

    Among the 58 patients with a DAS28 < 3.2 at baseline, treatment failed in 11 (19%) patients during the observation period. In this population, increased SEMA4A concentration was the only variable predicting the occurrence of treatment failure (HR 3.50, 95% CI 1.02–12.01). The presence of active synovitis detected on at least one joint on PDUS and other clinical or biological variables did not predict treatment failure (Table S2).

    In the 37 patients with a DAS28 < 2.6, treatment failure occurred in 4 patients (11%) and elevated SEMA 4A showed a trend for predicting treatment failure (HR 3.30, 95% CI 0.82–152.11, p = 0.069).

    Elevated SEMA4A concentration was also identified as the only predictor of flares (n = 16, 28%) in this subgroup of 58 patients with DAS28 < 3.2 (HR 3.68, 95% CI 1.33–10.17 ).

    Analysis of cohort 2 from Pelegrin Hospital, Bordeaux

    Study population

    A total of 40 patients (29 women, 73%) were included. These patients had a mean age of 57 ± 14 years, a mean disease duration of 5 ± 6 years, and active disease with a mean DAS28 of 5.12 ± 1.40. Positive rheumatoid factors and anti-CCP antibodies were detected in 27 (79%) and 28 (82%) patients, respectively. Erosions were present in 16 (40%) patients; 26 patients (65%) received corticosteroids. During the inclusion visit, 15 patients started MTX as first-line treatment and 25 started tocilizumab. Tocilizumab initiators were older, had longer disease duration and disease activity, and received corticosteroids more often than MTX initiators. Detailed characteristics of our study sample are given in Tables 1 and S3.

    Analysis of the course of SEMA4A serum levels according to response to treatment

    Of the 40 patients included, 4 experienced no response to treatment, 10 had a moderate response and 26 had a good response. As previously observed, baseline SEMA4A levels correlated with the DAS28 (r = 0.29, p = 0.038) and a trend was observed with CRP (r = 0.26, p = 0.10). At month 3, SEMA4A concentrations correlated with DAS28 and CRP (r = 0.31, p = 0.029 and r = 0.38, p = 0.017, respectively). Furthermore, baseline SEMA4A concentrations were significantly increased in active patients at inclusion, defined by a DAS28 > 3.2 (Fig. S2A). Interestingly, baseline SEMA4A levels were significantly higher in patients who otherwise experienced no or moderate response (198 ± 30 ng/ml) compared to patients with a good response (176 ± 24 ng/ml, p = 0.035) (Fig. S2B ). It was found that serum SEMA4A levels decreased significantly between m0 and m3, especially in the group of patients with good clinical response (Fig. S2C). This result was observed in the subgroups of patients starting MTX or tocilizumab (Fig. S2D,E).

    Source link

  • Aclarion Announces Signing of Strategic Partnership Letter of Intent with ATEC to Advance Commercialization of Nociscan

    Aclarion Announces Signing of Strategic Partnership Letter of Intent with ATEC to Advance Commercialization of Nociscan

    The partnership aims to incorporate Aclarion’s Nociscan surgical decision technology into ATEC’s AlphaInformatiX platform to better inform spine surgery

    ATEC is a medical device company committed to revolutionizing the approach to spine surgery through clinical differentiation

    Aclarion’s Nociscan is the first augmented intelligence platform to measure biomarkers of intervertebral disc health in the lumbar spine, helping doctors identify the location of chronic low back pain

    BROOMFIELD, CO, October 23, 2023 (GLOBE NEWSWIRE) – via NewMediaWire —Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and proprietary enhanced intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that the company has executed a non-binding Letter of Intent (“LOI”) to to form a strategic partnership with ATEC Spine, Inc., the wholly owned operating subsidiary of Alphatec Holdings, Inc. (Nasdaq: ATEC).

    By combining the unique structural data powered by ATEC’s AlphaInformatiX with the innovative biomarker data that allows Aclarion’s Nociscan solution to identify each intervertebral disc as painful or not, surgeons will have unprecedented data on one platform. The platform is designed to improve clinical outcomes while reducing overall procedural costs for patients with chronic back pain.

    Pat Miles, CEO of ATEC, commented: “Developing spinal technologies through innovation requires discipline, time, knowledge and resources. This collaboration with Aclarion reflects our belief in the importance of biochemical markers within the treatment paradigm. Nociscan is exactly the kind of innovation that can advance our shared goal of integrating and advancing technologies that improve the predictability and reproducibility of spine care.”

    Aclarion’s proprietary decision support tool, Nociscan, is the first evidence-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies.

    Aclarion’s published studies confirm the comparative advantage of Nociscan in achieving differentiated surgical outcomes. In April 2023, Aclarion announced a published, peer-reviewed 85% 2-year success rate for discogenic low back pain surgery in patients whose treatment strategy was consistent with Nociscan-identified discs. This result was a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0.07).1

    1 https://pubmed.ncbi.nlm.nih.gov/37014434/

    “We share a common vision with ATEC on the value of advanced decision support information to improve patient care. This strategic partnership is an important milestone for Aclarion. Pat and the ATEC team are revolutionizing spine surgery, and we appreciate their support,” said Brent Ness, CEO of Aclarion.

    The LOI is considering a multi-step strategic partnership. Under the LOI, ATEC and Aclarion will work together to identify Key Opinion Leader (KOL) surgeons who can evaluate the Nociscan technology. Feedback from these surgeons will form the basis for clinical evaluations designed to assess the utility of Nociscan in combination with EOS imaging, the foundation of ATEC’s AlphaInformatiX platform. Based on positive synergies, ATEC and Aclarion will jointly commercialize Nociscan in specific markets. In exchange for selected access to ATEC’s surgeon network for the evaluation and development of Nociscan, Aclarion will grant ATEC certain exclusive distribution rights to include Nociscan as part of an integrated procedural solution.

    Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disorders and low back pain. Conventional imaging and diagnostics provide valuable structural information, but are limited in identifying the source of the pathogenic pain.

    About Aclarion, Inc.

    Aclarion is a healthcare technology company that uses magnetic resonance spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers and enhanced intelligence algorithms to optimize clinical treatments. The company is entering the chronic low back pain market for the first time with Nociscan, the first evidence-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies. For more information please visit www.aclarion.com.

    About ATEC

    Alphatec Holdings, Inc. is, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging SA and SafeOp Surgical, Inc., a medical device company committed to revolutionizing the approach to spine surgery through clinical differentiation. ATEC’s organic innovation machineT.M is focused on developing new approaches that integrate seamlessly with the company’s growing AlphaInformatiX Platform to better inform surgery and achieve the goals of spine surgery more safely and reproducibly. ATEC’s vision is to be the standard bearer in the spine field. For more information visit us at www.atecspine.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on management’s current plans and expectations and are subject to a number of uncertainties and risks that could materially affect the company’s current plans and expectations, as well as its future results of operations and financial condition. These and other risks and uncertainties are discussed in more detail in our filings with the Securities and Exchange Commission. Readers are encouraged to read the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as other disclosures in the prospectus and subsequent filings with the Securities and Exchange Commission. . Forward-looking statements in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Revelation

    The information above has been prepared by Aclarion and reflects the opinion of Aclarion only. Nothing in this statement should be construed as any endorsement or approval of Aclarion or any of its products by ATEC.

    Investor contacts:
    Kirin M. Smith
    PCG Advice, Inc.
    646.823.8656
    ksmith@pcgadvisory.com

    Media contacts:
    Jodi Lamberti
    SPRIG advice
    612.812.7477
    jodi@sprigconsulting.com

    Source link

  • Playing tackle football may increase the risk of Parkinson’s disease

    Playing tackle football may increase the risk of Parkinson’s disease

    Identification of risk factors for Parkinson’s disease (PD) is essential for early diagnosis. Parkinson’s disease and parkinsonism, an umbrella term referring to motor symptoms common to Parkinson’s disease as well as other conditions, date back to the 1920s and have long been described in boxers. Repetitive head impacts from tackle football can also have long-term neurological consequences, such as chronic traumatic encephalopathy (CTE). But research on the association between participation in tackle football and PD is limited.

    In the largest study describing the link between participation in football and the likelihood of a reported diagnosis of Parkinson’s, Researchers at the BU CTE Center used a large online dataset of people concerned about having Parkinson’s and found that participants with a history of playing organized football had a 61% greater chance of having a reported diagnosis of Parkinson’s or Parkinson’s.

    In this study, the researchers evaluated 1,875 sports participants: 729 men who played football, mainly at the amateur level, and 1,146 men who played non-soccer sports and who served as a control group. Participants took part in Fox Insight, a longitudinal online study of people with and without Parkinson’s, sponsored by the Michael J. Fox Foundation for Parkinson’s Research.

    Notably, researchers found a link between playing football and a greater chance of receiving a diagnosis of parkinsonism or Parkinson’s, even after taking into account known risk factors for Parkinson’s disease. Additionally, the data revealed that players with longer careers and who played at higher levels of competition were more likely to have a reported diagnosis of parkinsonism or Parkinson’s. Football players who played at the college or professional level had a 2.93 higher odds of receiving a PD diagnosis compared to those who just played at the youth or high school level. The age of first exposure to football was not associated with the likelihood of having a reported parkinsonism or Parkinson’s diagnosis.

    “Playing tackle football could be a contributing risk factor for Parkinson’s disease, especially among people already at risk due to other factors (e.g. family history). However, the reasons for this relationship are not clear and we also know that not everyone who plays tackle football will develop neurological disorders later in life, meaning that many other risk factors are at play,” says corresponding author Michael L. Alosco, PhD, associate professor of neurology at Boston University Chobanian & Avedisian School of Medicine.

    The researchers also emphasized that they compared the football players to another group of athletes, a notable strength of the study. Furthermore, most participants played tackle football exclusively at the amateur level, which contrasts with most research to date that has focused on professional athletes.

    “Previous research has focused on the association between American football and the risk of CTE. But similar to what has been historically seen in boxers, American football could also influence the risk of other neurodegenerative disorders such as Parkinson’s disease,” says Hannah Bruce , MSc, first. author and research specialist at Boston University Chobanian & Avedisian School of Medicine.

    The researchers acknowledge several limitations to their findings and caution that the work is still preliminary. It was a convenience sample of people who were enriched for having Parkinson’s disease and who were largely white, limiting the generalizability of the findings. Parkinson’s diagnosis was also self-reported by participants via online assessments, but no objective in-person evaluations were conducted.

    This work was in collaboration with the Michael J. Fox Foundation for Parkinson’s Research, the sponsor of Fox Insight. The Fox Insight study was used to collect and aggregate the data used in this manuscript. Grant funding also came from NINDS (U54NS115266; K23NS102399).

    Source link

  • Silky steamed eggs | GF, DF

    Silky steamed eggs | GF, DF

     

    Are you stuck in a boring breakfast rut?

    This will confuse it!

    Our Silky Steamed Eggs recipe is a protein-rich breakfast dish that everyone can enjoy.

    Not only is this silky custard packed with bone-boosting nutrients like calcium and vitamin D, it’s also paleo-friendly, keto-friendly, gluten-free, and dairy-free.

    Try it today!

    Bone Coach Recipes | Silky steamed eggs | Bone loss Bone Healthy diet Nutrients Osteoporosis

    Silky steamed eggs | GF, DF | BoneCoach™ Recipes

    SERVES: 1

    TOTAL TIME: 25 minutes

    Ingredients

    2 large eggs

    200 ml chicken bone stock

    1 teaspoon (5 ml) coconut aminos

    2 teaspoons (10 ml) chopped green onions

    Directions

    1) Beat the eggs with the stock. Pour the egg mixture through a fine sieve to remove any bubbles into a 6-inch bowl. Cover the bowl with a tight-fitting lid or aluminum foil.

    2) Prepare a steamer basket with 2 inches of water and bring to the boil over medium heat. Place the bowl in the steamer and cover with a lid. Let it boil for 10 minutes, then turn off the heat and let it cook in the residual heat for another 10 minutes.

    3) Carefully remove the dish from the steam basket. Drizzle the coconut aminos over the silky egg custard and garnish with green onions. Enjoy immediately.

    Recipe created by BoneCoach™ Team Dietitian Amanda Natividad-Li, RD & Chef.

    Medical disclaimer

    The information shared above is for informational purposes only and is not intended as medical or nutritional therapy advice; it does not diagnose, treat or cure any disease or condition; it should not be used as a substitute or substitute for medical advice from physicians and trained medical professionals. If you are under the care of a healthcare professional or are currently taking prescription medications, you should discuss any changes in your diet and lifestyle or possible use of nutritional supplements with your doctor. You should not stop prescribed medications without first consulting your doctor.

    Source link

  • Biogennix launches OsteoSPAN fiber matrix

    Biogennix launches OsteoSPAN fiber matrix

     

    IRVINE, California, October 24, 2023 / OrthoSpineNews / – Irvine-based Biogennix, an osteobiology company that develops, manufactures and distributes proprietary bone graft products used for bone fusion procedures, today announced the launch of its new OsteoSPAN fiber matrix.

    OsteoSPAN Fiber Matrix consists of 100% demineralized cortical fibers and is designed for optimized handling, while providing verified osteoinductive potential and an osteoconductive scaffold that supports cellular bone formation and stimulates fusion. OsteoSPAN Fiber Matrix is ​​also processed to provide fast, consistent hydration and fluid retention while resisting irrigation.

    The OsteoSPAN fiber matrix is ​​malleable and cohesive when hydrated with blood or bone marrow, and expands to conform to irregular bone voids. The product is available in volumes of 1cc, 2.5cc, 5cc and 10cc.

    “OsteoSPAN Fiber Matrix is ​​Biogennix’s first allograft product,” said Mark Borden, CTO of Biogennix. “We are excited to expand our portfolio with allografts that will complement our extensive synthetic offering and give us access to a new segment of the bone graft market.”

    ###

    Biogennix® is a fully integrated osteobiology company headquartered in Irvine that develops, manufactures and distributes proprietary bone graft products used in bone fusion procedures. Biogennix is ​​committed to advancing the technology behind natural bone grafting solutions, delivering outstanding quality with exceptional value and customer-focused excellence. More information can be found at biogennix.com.

    Media contact:
    Paul Williams
    310-569-0023
    paul@medialinecommunications.com

    Source link

  • Healing Energy for Bones and Brain with Dr. Louise Swartswalter

    Healing Energy for Bones and Brain with Dr. Louise Swartswalter

     

    We all feel the weight of stress on our shoulders, but did you know THAT could also be THAT same stress? influence the strength of our bones?

    Have you ever thought about how healing energy can not only calm your mind, but also… play a crucial role in bone health?

    And what if the key to managing that daily tension went beyond simple relaxation and relaxation? dived deep into the energy fields around us?

    Prepare to be enlightened!

    I had the pleasure of sitting down Dr. Louise Swartswalter, a naturopath, frequency medicine practitioner and transformational coach. Join us as we explore her innovatively BRAIN system and take a tour of its calming effects “spirit gemstones” technique, designed to improve focus while promoting healing energy and healthy bones.

    Episode timeline

    0:00 – Episode begins

    1:26 – Meet our guest, Dr. Louise Swartswalter

    2:37 – Dr. Swartswalter’s journey to holistic health: mind, body, spirit and energetic field

    6:11 – The connection between the brain and overall health, with an emphasis on bone health

    8:05 – Digging Deeper: How Stress Affects Bone Health

    9:07 – Dr.’s best stress-relieving tools Swartswalter

    10:12 – Mind Gems tour

    14:07 – The holistic approach of the BRAIN system explained

    16:14 – Impact of diet, exercise and hormones on bone and brain health

    18:15 – A closer look at how parathyroid hormone affects osteoporosis risk

    20:16 – Detoxing heavy metals for osteoporosis prevention and better bone health

    22:09 – The role of exercise, especially weight bearing, in fighting osteoporosis as we age

    25:13 – The importance of sleep in brain rejuvenation

    28:25 – Introducing the Brain Soul Success Assessment for optimal brain health

    29:17 – Where to find Dr. Swartswalter and other sources

    Sources mentioned

    **Show notes @ https://bonecoach.com/louise-swartswalter-brain-soul-success

    Below you will find resources from Dr. Louise!

    >> Click here to take your FREE Brain-Soul Success Assessment

    What can you do to support your bone health and this podcast?

    1. Press the “Subscribe” button on your respective podcast player (i.e. Apple, Google, Spotify, Stitcher, iHeart Radio and TuneIn). Never miss an episode that can help improve your bone health.

    2. Leave a review. The more positive ratings and reviews and the more subscribers we have, the more people can find us and get the answers to the questions they need. Thank you! 🙂

    3. Tell a friend about The Bone Coach Podcast or share via text, email or social. Do you know of a Facebook group where people can benefit from this information? Feel free to click any of the share buttons below.

    About Dr. Louise Swartswalter:

    Dr. Louise Swartswalter is a naturopath, frequency medicine practitioner, transformational coach, speaker, mentor and healer serving women and men around the world. She is the creator of the Brain Soul Success Academy and the BRAIN System, a unique multi-dimensional system that works simultaneously on the mind, body, soul and energetic field.

    Dr. Louise has 30 years of experience helping people achieve optimal brain power and success in life and business.

    Her team of certified Brain Soul Success Coaches helps people around the world transform their lives and grow their businesses. Dr. Louise has been a guest on KKOB radio and KOB-TV Good Day New Mexico and has been featured in Albuquerque Magazine’s Top Documentation.

    Medical disclaimer

    The information shared above is for informational purposes only and is not intended as medical or nutritional therapy advice; it does not diagnose, treat or cure any disease or condition; it should not be used as a substitute or substitute for medical advice from physicians and trained medical professionals. If you are under the care of a healthcare professional or are currently taking prescription medications, you should discuss any changes in your diet and lifestyle or possible use of nutritional supplements with your doctor. You should not stop prescribed medications without first consulting your doctor.

    Source link

  • New concussion headset shows when it’s likely safe to return to play

    New concussion headset shows when it’s likely safe to return to play

     

    A new digital headset designed to measure changes in brain function could change decisions about how quickly an athlete is ready to return to play after a concussion. In an evaluation of the device, researchers at UC San Francisco found that it revealed brain changes even in athletes whose concussion symptoms had disappeared, suggesting they may be playing too fast.

    Although the device has not yet been approved by the Food and Drug Administration (FDA), it could fill an important niche among athletes, doctors, trainers and coaches concerned about the long-term effects of repeated sports-related concussions. These include chronic traumatic encephalopathy, Alzheimer’s disease and Parkinson’s disease.

    The headset — patented by UCSF and licensed by MindRhythm, a medical technology company — recorded changes in what the researchers call “headpulse,” which are subtle forces exerted on the skull as the heart contracts.

    The researchers observed how the device performed in 101 young adults who played Australian Rules Football and had suffered 44 concussions. The results appeared on August 11, 2023 JAMA network opened.

    On average, the changes detected by the headset lasted twelve days longer than the players’ symptoms.

    “We found a mismatch between the symptoms and the changes in biometrics recorded by the device,” said Cathra Halabi, MD, of the UCSF Department of Neurology and the Weill Institute for Neurosciences, the study’s first author. “This raises concerns about relying on symptoms for return-to-play decisions. Delays may be recommended for symptom-free athletes if head pulse abnormalities persist.”

    Researchers said the headset should be used in conjunction with medical expertise.

    “We believe it can provide crucial objective biometric measurements that can be used by athletes and medical professionals to decide when to return to play,” said senior author Wade S. Smith, MD, PhD, chief of the UCSF Neurovascular Division and co -author. founder of MindRhythm. “The headset is also used to monitor athletes afterwards to ensure measures remain within the normal range.”

    Concussion is at risk when physical activity is resumed

    Exercising with a concussion puts the brain at increased risk of damage. “There is a rare condition called second impact syndrome, where a second concussion shortly afterward can cause almost immediate brain death,” Smith said.

    More commonly, playing sports with a concussion can result in an increased risk of subsequent brain injury, due to symptoms such as slowed reaction time, impaired balance, or impaired vision.

    “Recurrent concussions that occur in close succession can lead to more debilitating symptoms that last longer, keeping athletes out of the game,” Halabi said.

    Although the headset was tested in young adults, its use may eventually be expanded to minors. MindRhythm hopes to receive FDA approval within a year, says co-founder and CEO John Keane. “The plan is to make the technology available to the medical community, with the most likely areas of interest being sports medicine and concussion clinics,” he said.

    Concussed athletes may be able to record their own biometric measurements, the researchers noted. Doctors or sports trainers would monitor the data remotely and provide advice on when it is safe to resume sports and other physical activities.

    Source link

  • Centinel Spine® PMA application for first-of-its-kind 2-level prodisc® C Vivo and prodisc C SK Match-the-Disc™ Cervical Total Disc Replacement System submitted and followed up with substantive review

    Centinel Spine® PMA application for first-of-its-kind 2-level prodisc® C Vivo and prodisc C SK Match-the-Disc™ Cervical Total Disc Replacement System submitted and followed up with substantive review

    The clinical trial evaluated the safety and effectiveness of prodrive C Vivo and prodisc C SK system by comparing it to an approved total disc replacement (TDR) product as a check for 2-level indications.This is the first IDE study to allow surgeons to choose from two different TDR devices to treat each surgical level separately.The IDE trial involved 431 subjects at 29 locations in the United States.

    WEST CHESTER, Pa., Oct. 26, 2023 /PRNewswire/ — Centinel Spine®LLC, (“the Company”), the leading global medical device company addressing cervical and lumbar spine diseases with the world’s most clinically proven total disc replacement (TDR) technology platform (prodisk®), today announced that the Food and Drug Administration (FDA) has accepted the submission of its Premarket Approval (PMA) application submitted for the Investigational Device Exemption (IDE) study evaluating the company’s benefitsdrive C I’m alive and prodisk C SK cervical TDR system. The filing date for the company’s PMA application was September 27, 2023, and the submission is now under substantive review by the FDA.

    The prospective, randomized clinical trial was designed to evaluate the safety and effectiveness of the prodrive C I’m alive and prodisk C SK system by comparing it to an approved TDR product as a control for 2-level indications, making it the first and only trial of its kind with two investigational devices and a TDR control. The study completed enrollment in June 2023 and included 431 subjects at 29 US sites and allowed surgeons to select the study device: the prodrive C I’m alive and/or prodisk C S.K—based on patient anatomy, as well as other surgical factors. The ability to individually treat each level of disease at two levels provides surgeons with both more options and opportunities to tailor the intervertebral disc to the patient’s anatomical needs.

    One of the lead investigators in the study, orthopedic spine surgeon Dr. Brian Perri of DOCS Health in Los Angeles, CA, commented on this important milestone: “Centinel Spine is once again working to demonstrate innovation, safety and effectiveness in their line of cervical disc replacements through this unique study. I hope for FDA approval soon, which will make Centinel Spine the first company to offer multiple disc designs for two-level procedures and allow the surgeon to select the best cervical total disc replacement for each level treated.

    “The proffesionaldisk C Alive and prodisk C SK The 2-level cervical disc clinical trial was unique in two respects,” said Steve Murray, CEO of Centinel Spine. “It is the first cervical study to use total disc replacement devices in both study arms, and it is the only study to offer disc options in the study arm according to surgeon preference based on patient anatomy. This trial is in line with Centinel Spine’s strategy to be the only company providing both cervical and lumbar intraoperative prostate products.disk options for one- and two-level total drive replacement procedures. We look forward to the FDA’s careful review of the PMA submission.”

    The proffesionaldrive C I’m alive system has been in clinical use internationally since 2009 and is currently one of the most implanted TDR devices in the world. The device has a keelless fixation and combines a unique anatomically designed superior endplate with lateral spikes to optimize fit and provide immediate fixation. The proffesionaldisk C SK The device features a flat end plate designed for optimized implant positioning, allowing surgeons to explore the individual patient’s anatomy – with a low-profile central keel that provides immediate fixation and allows for a streamlined keel preparation technique.

    More information about the clinical trial can be found at www.clinicaltrials.gov using the identifier NCT04012996.

    About Centinel Spine, LLC
    Centinel spine®LLC is the leading global medical device company addressing cervical and lumbar spine diseases with the world’s most clinically proven total disc replacement (TDR) technology platform (prodisk®). The company’s prodisk technology is the most studied and clinically proven TDR system in the world, validated by more than 540 published articles and more than 250,000 implantations worldwide.

    Centinel Spine continues to advance its pioneering culture and corporate mission to become a catalyst for change in the spine industry and change the way spine surgery is experienced. The proffesionaldisk platform remains the only technology with multiple motion preservation solutions for both cervical and lumbar anterior column reconstruction.

    For more information, please visit the company’s website at www.CentinelSpine.com or contact:

    Varun Gandhi
    Finance Director
    900 Airport Road, Suite 3B
    West Chester, PA 19380
    Phone: 484-887-8871
    Email: v.gandhi@centinelspine.com

    SOURCE Centinel Spine, LLC

    Source link

  • Global Scoliosis Management Market Report 2023: Market to Grow by $1 Billion by 2030 – Spinal Fusion Surgery Offers Major Opportunities

    Global Scoliosis Management Market Report 2023: Market to Grow by $1 Billion by 2030 – Spinal Fusion Surgery Offers Major Opportunities

    Dublin, October 26, 2023 (GLOBE NEWSWIRE) – The report “Scoliosis Management – ​​​​Global Strategic Business Report” has been added to ResearchAndMarkets.com’s to offer.

    The global scoliosis treatment market will reach $3.8 billion by 2030

    The global scoliosis treatment market, estimated at USD 2.8 billion in the year 2022, is expected to reach a revised size of USD 3.8 billion by 2030, with a CAGR of 4.1% over the analysis period 2022-2030.

    This data includes an analysis of the Thoracolumbosacral Orthosis (TLSO) and related orthosis markets worldwide. It includes current, historical, and future annual sales figures in thousands of dollars for the years 2022 through 2030, along with percentage compound annual growth rates (%CAGR).

    The analysis is segmented into different product types, including TLSO, Cervical Thoracic Lumbar Sacral Orthosis (CTLSO), Lumbosacral Orthosis (LSO), and Other Product Types. Furthermore, within these product types a distinction is made between the Pediatric and Adult segments.

    Thoracolumbosacral orthosis (TLSO), one of the segments analyzed in the report, is expected to register a CAGR of 4.4% and reach $2.9 billion by the end of the analysis period. Growth in the Cervical Thoracic Lumbar Sacral Orthosis (CTLSO) segment is estimated at 3.7% CAGR over the next eight years.

    The US market is estimated at $987.6 million, while China is expected to grow at a CAGR of 5%

    The US scoliosis treatment market is estimated to reach USD 987.6 million by the year 2022. China, the second largest economy in the world, is expected to reach a projected market size of USD 422.1 million by 2030, at a CAGR of 5% over recent years. analysis period 2022 to 2030.

    The data provides a 16-year perspective, breaking down the percentage of value sales for different geographic regions, including the US, Canada, Japan, China, Europe, Asia Pacific and the rest of the world, for the years 2014, 2023 and 2030 Finally, it provides a comprehensive analysis of the scoliosis treatment market, including annual sales figures from 2014 through 2030, and segmented analyzes for different geographic regions.

    Other notable geographic markets include Japan and Canada, each expected to grow by 3.1% and 3.4%, respectively, over the 2022-2030 period. Within Europe, Germany is expected to grow at a CAGR of approximately 4.1%.

    This comprehensive report also provides detail on the approaches that leading market competitors such as Aspen Medical Products, Bauerfeind AG and Boston Orthotics & Prosthetics are taking, providing invaluable insights that you as an executive can leverage.

    What’s new?

    • Special discussions on the global economic environment and market sentiment
    • Coverage on global competitiveness and key market shares of competitors
    • Multi-region market presence analysis – Strong/active/niche/trivial
    • Online interactive peer-to-peer collaborative custom updates
    • Access to digital archives and a trademarked research platform
    • Free updates for a year
    • Access curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers through interviews, podcasts, press statements and event keynotes

    MARKET OVERVIEW

    • Scoliosis: An abnormal lateral curvature of the spine
    • Scoliosis Management/Treatment Options
    • COVID-19 is casting a shadow on the scoliosis treatment market
    • Competition
    • Scoliosis Management – ​​Percentage Market Share of Key Competitors Globally in 2023 (E)
    • Competitive Market Presence – Strong/Active/Niche/Trivial for Global Players in 2023 (E)
    • Great startup ecosystem
    • Global market analysis and prospects
    • The global scoliosis management market will demonstrate steady growth driven by innovations and advancements
    • North America holds a leading position in the global scoliosis management market
    • ThoracoLumboSacral Orthosis (TLSO) dominates the market
    • AIS remains the primary disease type segment
    • Pediatric/adolescent as an important age group segment
    • Hospitals and ASCs claim leading share
    • Technological advancements as pulsating trends drive the scoliosis treatment market forward
    • Increase R&D activity to drive market expansion
    • Market restrictions
    • Market challenges
    • Recent market activity
    • GLOBAL BRANDS

    MARKET TRENDS & DRIVERS

    • Rising prevalence of idiopathic and congenital scoliosis drives market growth
    • Spinal fusion surgery offers great opportunities
    • The demand for fusionless scoliosis surgery is increasing
    • Tying the vertebral body provides traction
    • Schroth therapy – a useful approach to treat scoliosis
    • Strong focus on minimally invasive spine surgery and increasing use of navigation and robotics in scoliosis surgery to increase prospects
    • Increasing cases of scoliosis in adults and a growing aging population to propel the adult segment
    • Increase healthcare spending to stimulate growth
    • Recent technological advances/innovations in the scoliosis treatment market
    • New Satellite Rod-Based Sequential Correction for Severe Rigid Spinal Deformities to Reduce Surgical Risks and Other Complications
    • ApiFix system for correcting moderate scoliosis with single curves
    • Shriners Hospitals for Children’s The Tether, a device for treating scoliosis, receives FDA approval
    • Minimally invasive spine surgeries are becoming commonplace, but long-term research into results is essential for wider adoption
    • Disruptive technologies in the spine space – a review
    • 3D printed braces have potential to improve the treatment of scoliosis

    FOCUS ON SELECTED PLAYERS(Total 91 recommended)

    • Aspen Medical Products, LLC
    • Bauerfeind AG
    • Boston Orthoses and prosthetics
    • Chaneco
    • Enovis
    • Fitted, Inc.
    • Horton’s Orthotics and Prosthetics
    • Lawall Prosthetics and Orthotics
    • Optec USA, Inc.
    • Orthotec
    • Ottobock SE & Co. KGaA
    • Spinal Technology Inc.
    • Real

    For more information about this report, visit https://www.researchandmarkets.com/r/ozemky

    About ResearchAndMarkets.com
    ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

    Source link

  • Effects of trunk training using motor imagery on the control ability and balance function of the trunk in stroke patients | BMC Sports sciences, medicine and rehabilitation

    Effects of trunk training using motor imagery on the control ability and balance function of the trunk in stroke patients | BMC Sports sciences, medicine and rehabilitation

    General information

    Post-stroke patients with motor dysfunction who were hospitalized in the Department of Rehabilitation Medicine of our hospital from January 1, 2020 to January 1, 2022, aged 50 to 70 years old, were selected.

    Inclusion criteria: [12] ① The patient met the diagnostic criteria for stroke established at the Fourth National Academic Conference on Cerebrovascular Diseases in 1995, [13, 14] and stroke was diagnosed as the primary disease on CT or MRI. ② The time between disease onset and enrollment ranged from two weeks to three months. ③ The patient’s vital signs were stable and the patient was conscious, able to understand the instructions and cooperate with the rehabilitation training. ④ The patient’s score on the Kinesthetic and Visual Imagery Questionnaire (KVIQ) was ≥ 25 points. ⑤ The patient signed the required informed consent form. ⑥ Age between 50 and 70 years.

    Exclusion criteria: [14] ① The patient suffered from severe cardiac, hepatic or renal insufficiency, a malignant tumor, etc. ② The patient suffered from impaired consciousness, aphasia, mental disorder or severe cognitive impairment. ③ The patient has had other craniocerebral diseases or traumatic sequelae in the past. ④ The patient has previous severe osteoarticular disorders causing abnormal trunk function.

    Finally, a total of 100 patients with stroke and motor dysfunction were included, and they were divided into a control group and a trial group according to the random number table, with 50 cases in each group. There was no significant difference (P > 0.05) in general data such as gender, age, disease course and KVIQ between the two groups, and they were comparable. See Table 1 for details. This study was approved by the local ethics committee (approval number: 2018-ethical review-189) and conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent.

    Table 1 Comparison of general data of patients such as gender, age, disease course and lesion site between the two groups

    Treatment methods

    The patients in the control group underwent routine rehabilitation therapy and remained in the supine position in the same environment for the same amount of time as the combined trunk motor imagery therapy. Meanwhile, the trial group received both routine rehabilitation therapy and combined trunk motor imagery therapy.

    Routine rehabilitation therapy

    The training included proper limb positioning, neuromuscular promotion techniques, such as the proprioceptive neuromuscular facilitation technique (PNF), Rood’s approach, motor relearning, occupational therapy, daily living training and traditional therapy. The participants received routine rehabilitation therapy for five hours a day, five times a week, for a period of four weeks.

    Motor image therapy

    The motor imagery therapy training consisted of six steps: [4, 14] ① Illustration of the task: The therapist first demonstrated and explained the content of the imagery training, asking the patients to carefully observe and identify which part of the limb was ‘active’, what kind of movement was to be performed, and the normal movement to master. feeling. ② Preview: Patients were asked to re-imagine the relevant movements. ③ Motor imagery: Patients listened to the motor imagery instruction tape and practiced the imagery. ④ Rehabilitation training: the patients repeatedly practiced the movements of imagery training. ⑤ Problem solving: The patients learned relevant skills through repeated practice. ⑥ Practical application: the patients convert relevant skills into practical skills. Before the motor images, a video of a normal person’s trunk movements was shown, including stable trunk movements with a Bobath ball, and balance movements while sitting, standing, and reaching to move a water cup. The 10-minute video and audio were shown to patients via a computer in a quiet treatment room. During each training session, patients were instructed to close their eyes and sit on a comfortable chair with their bodies relaxed. The patients then imagined the movement of their body based on the specific motor imagery instructions in the video. During the treatment, the therapist occasionally interrupted the patients to ask questions, to see if they could concentrate on the images of the physical movement. At the end of the session, the patients were asked to refocus their attention on their surroundings, after which they were sent back to their room and asked to feel their physical being. The patients were then asked to pay attention to the environmental sounds. Finally, the narrator counted down from 10 to 1, and the patients were asked to open their eyes when the countdown reached 1. A motor imagery video was shown only during the first treatment, after which the patients underwent motor imagery training according to the motor imagery. guidelines for imagery. The motor imagery therapy sessions were conducted for 30 minutes each, with a frequency of five times per week, for a total of four weeks.

    Observation indicators and evaluation methods

    The evaluation of the patient’s trunk control was performed before treatment and four weeks after treatment using Sheikh trunk control evaluation. The simple Fugl-Meyer assessment (FMA), the Berg rating scale (BBS), and the balance feedback trainer were used to evaluate the motor and balance functions of the patients. In addition, before and after treatment, the sEMG signals of the bilateral erector spinae and rectus abdominis in the maximum flexion and extension range at a uniform speed under the sitting position were measured by sEMG signals. All evaluations were performed in a blinded manner by the same evaluator.

    Sheik Hull Check Evaluation

    Sheikh is a scale for evaluating the ability to control the trunk. It involves four movements: turning from the supine position to the hemiplegic side, turning to the healthy side, sitting upright from the supine position and maintaining balance in a sitting position on the bed. The scoring method is: 0 points for non-completion, 12 points for completion but needing some assistance (grasping or leaning on an object), and 25 points for normal completion. A higher total score indicates better trunk control.

    BBS rating

    The balance function is divided into 14 items, from easy to difficult, and each item is scored based on a five-point scale: 0, 1, 2, 3, and 4. The highest score is 4 points and the lowest score is 0 points. . The highest integral score is 56 points, the lowest is 0 points. The higher the score, the better the balance function.

    Evaluation of motor functions

    FMA is used to evaluate motor function in patients. The highest score is 100. The higher the score, the better the patients’ motor functioning will be.

    Evaluation of balance feedback training equipment

    The ProKin 254P (PK-254P) balance feedback training device, manufactured by TecnoBody Ltd., Italy, was used to test the postural stability of the patients. Stability tests were performed in standing position with eyes open using the static mode of the PK-254P balancer. The standard standing posture includes: ① Bilaterally symmetrical standing with A1A5 as central axis. ② The patients raise their heads and look straight ahead. ③ Both upper limbs are naturally placed on either side of the body. ④ The medial edges of both feet are 10 cm apart and the highest point of the bilateral arches is on axis A3A5. Observation parameters are as follows: movement length, movement area, mean front-back movement speed, and mean left-right movement speed.

    sEMG signal acquisition

    While the patients are seated on a square stool, their trunk is subjected to anterior flexion and posterior extension in the maximum range at uniform velocity. The Shanghai NCC 8-channel sEMG signal acquisition system was used to acquire the bilateral erector spinae and rectus abdominis myoelectric signals. The electrodes were taped to the 3 cm lateral opening on the left and right sides of the L3 spinous process (erector spinae) and the 3 cm lateral opening on the left and right sides 3 cm above the navel (rectus abdominis). The conductive diameter of the electrodes was 1 cm and the distance between the electrodes was 2 cm. Dandruff and oil were removed with a fine gauze and alcohol before testing. The root mean square (RMS) of myoelectric signals was then analyzed. The test was repeated three times with an interval of 30 seconds to obtain the average value. The RMS of the bilateral rectus abdominis and erector spinae of the two groups was evaluated before treatment and four weeks after treatment.

    static analysis

    SPSS software version 16.0 was used to analyze the data. The measurement data is expressed as (\(\bar x \pm s\)). Parametric statistics were applied when the data collected met the assumptions of homogeneity of variance and normal distribution. When these assumptions were not met, non-parametric statistics were used. The paired sample T-test was used for pre- and post-treatment comparison within the same group, while the independent sample T-test was used for between-group comparison, and P< 0.05 indicated that the difference was statistically significant.

    Source link